These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22647435)

  • 1. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
    Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
    MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
    Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
    MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
    Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
    Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
    van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
    Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
    Nickerson-Nutter C; Tchistiakova L; Seth NP; Kasaian M; Sibley B; Olland S; Zollner R; Brady WA; Mohler KM; Baum P; Wahl A; Herber D; Vugmeyster Y; Wensel D; Wolfman NM; Gill D; Collins M; Dunussi-Joannopoulos K
    Rheumatology (Oxford); 2011 Jun; 50(6):1033-44. PubMed ID: 21258049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
    Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
    Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
    Pedersen AE; Jungersen MB; Pedersen CD
    Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
    Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
    Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20-targeted therapy: the next generation of antibodies.
    van Meerten T; Hagenbeek A
    Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanisms of action of rituximab in the elimination of tumor cells.
    Johnson P; Glennie M
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):3-8. PubMed ID: 12652458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.